Categories: FeaturedHealthLatest

AstraZeneca Vaccine Less Effective Against South Africa Variant

AstraZeneca Plc’s Covid-19 vaccine has shown limited efficacy against mild disease caused by the variant first identified in South Africa, according to early data in a small phase trial.

Efficacy against severe Covid-19 cases, hospitalization and deaths was not yet determined, “given that subjects were predominantly young healthy adults,” a spokesperson for AstraZeneca said in a statement.

None of the participants in the study died or was hospitalized, according to the Financial Times, which first reported on findings of the study.

The study, with a relatively small sample size of more than 2,000 individuals, hasn’t yet been peer-reviewed and is due to be published on Monday, the newspaper said. Patients in the randomized, double-blind study had a median age of 31.

“We do believe our vaccine could protect against severe disease, as neutralising antibody activity is equivalent to that of other Covid-19 vaccines that have demonstrated activity against more severe disease, particularly when the dosing interval is optimised to 8-12 weeks,” the AstraZeneca spokesperson said.

Initial data indicates other immune responses, such as T-cell responses, may remain intact in the South African variant, the spokesperson added.

The variant first identified in South Africa is emerging as a key threat to the world’s prospects for ending the pandemic as countries roll out initial vaccine doses. Although vaccine makers said their shots appear to maintain effectiveness against the UK variants, pharma companies are racing to develop booster shots against new variants as the virus evolves.

Oxford University and AstraZeneca have started adapting their vaccine against this variant, the spokesperson said. Should it be needed, they will advance through clinical development so that it is ready for autumn delivery.

Earlier this week, Astra’s executive vice president for biopharmaceutical research scaled back expectations for how the vaccine would work against the variant.

“We’re not going to be surprised to see reduced efficacy,” Mene Pangalos said. “It’s to be expected that there will be reduced activity.”

Bloomberg 

 

 

Follow us on:

AriseNews

Recent Posts

Gbadebo Rhodes-Vivour: Commercialisation Of GMO Seeds Can Take Away Nigeria’s Food Sovereignty, Cause Health Issues

Gbadebo Rhodes-Vivour has condemned the commercialisation of GMO seeds, warning of threats to Nigeria’s food…

8 hours ago

Usyk Defeats Fury on Points in Riyadh to Retain Heavyweight Championship Title

Oleksandr Usyk has secured victory over Tyson Fury in Riyadh, successfully defending his heavyweight championship…

13 hours ago

Albania to Ban TikTok for a Year After Schoolboy’s Death Sparks Concerns

Albania plans a one-year TikTok ban from January after a schoolboy’s death sparks concerns over…

16 hours ago

Suspect Remanded in Custody Over Deadly Attack at German Christmas Market

A suspect accused of killing five people by driving into a crowded Christmas market in…

17 hours ago

US Fighter Jet ShotDown in Red Sea ‘Friendly Fire’ Incident Amid Heightened Tensions

A US Navy F/A-18 Hornet was mistakenly shot down over the Red Sea by the…

17 hours ago

NNPC, Dangote Refinery Slash Petrol Prices to N899 Per Litre Amid Rising Competition

NNPC has reduced petrol ex-depot price to N899 per litre, sparking competition with Dangote Refinery…

17 hours ago